BBWI Stock Analysis: Bath & Body Works | NYSE
Specialty Retail | NYSE, USA | Market Cap: 3.519m USD | 12M Return: -30.9% | US0708301041 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 123M
EPS Trend: 16.8%
Qual. Beats: 1
Rev. Trend: -86.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bath & Body Works, Inc. (BBWI) is a U.S.-based specialty retailer focused on personal care and home fragrance products, including 3-wick candles, diffusers, fine fragrance mists, body wash, hand soaps, lotions, creams, and sanitizers sold under the Bath & Body Works brand and other labels. The company operates an omnichannel model, distributing its products through its own retail stores and e-commerce sites in the United States and Canada, while expanding internationally via franchise, license, and wholesale arrangements with third-party partners. Originally part of L Brands, Inc., the company was renamed Bath & Body Works, Inc. in August 2021, reflecting its identity as a single-category specialty retailer. Founded in 1963 and headquartered in Columbus, Ohio, BBWI competes within the Consumer Discretionary sectors specialty retail sub-industry, where the business model is typically defined by frequent product rotation, seasonal fragrance launches, and a combination of physical store presence and direct-to-consumer digital sales.
- Home fragrance category led by 3-wick candles anchors revenue
- International franchise partnerships expand into new global markets
- Consumer discretionary spending pressures same-store sales traffic
- Capital returns through dividends and debt reduction continue
| Net Income: 781.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 3.73 > 1.0 |
| NWC/Revenue: 4.76% < 20% (prev 5.47%; Δ -0.71% < -1%) |
| CFO/TA 0.25 > 3% & CFO 1.27b > Net Income 781.0m |
| Net Debt (5.08b) to EBITDA (1.45b): 3.50 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (202.0m) vs 12m ago -4.54% < -2% |
| Gross Margin: 44.12% > 18% (prev 44.60%; Δ -0.48% > 0.5%) |
| Asset Turnover: 144.6% > 50% (prev 153.1%; Δ -8.46% > 0%) |
| Interest Coverage Ratio: 4.49 > 6 (EBIT TTM 1.21b / Interest Expense TTM 269.0m) |
| A: 0.07 (Total Current Assets 2.05b - Total Current Liabilities 1.71b) / Total Assets 5.16b |
| B: -0.24 (Retained Earnings -1.21b / Total Assets 5.16b) |
| C: 0.24 (EBIT TTM 1.21b / Avg Total Assets 4.99b) |
| D: -0.17 (Book Value of Equity -1.05b / Total Liabilities 6.21b) |
| Altman-Z'' = 1.12 = BB |
| DSRI: 1.20 (Receivables 154.0m/131.0m, Revenue 7.21b/7.37b) |
| GMI: 1.01 (GM 44.60% / 44.12%) |
| AQI: 0.92 (AQ_t 0.19 / AQ_t-1 0.21) |
| SGI: 0.98 (Revenue 7.21b / 7.37b) |
| TATA: -0.10 (NI 781.0m - CFO 1.27b) / TA 5.16b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of September 19, 2026, the stock is trading at USD 17.40 with a total of 8,726,984 shares traded. Over the past week, the price has changed by -6.30%, over one month by -12.28%, over three months by -14.50% and over the past year by -30.94%.
Current recommended Stop Loss: 16.10 (which is 7.5% or 1.4 ATR below the current price).
Bath & Body Works has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy BBWI.
- StrongBuy: 7
- Buy: 4
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 24.1 | 38.3% |
P/E Trailing = 4.6533
P/E Forward = 6.5232
P/S = 0.4881
P/B = 1403.3759
P/EG = 0.7264
Revenue TTM = 7.21b USD
EBIT TTM = 1.21b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 3.37b USD (from longTermDebt, last quarter)
Short Term Debt = 447.0m USD (from shortTermDebt, last quarter)
Debt = 5.87b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.13b
Net Debt = 5.08b USD (calculated: Debt 5.87b - CCE 794.0m)
Enterprise Value = 8.60b USD (3.52b + Debt 5.87b - CCE 794.0m)
Interest Coverage Ratio = 4.49 (Ebit TTM 1.21b / Interest Expense TTM 269.0m)
EV/FCF = 8.34x (Enterprise Value 8.60b / FCF TTM 1.03b)
FCF Yield = 11.99% (FCF TTM 1.03b / Enterprise Value 8.60b)
FCF Margin = 14.30% (FCF TTM 1.03b / Revenue TTM 7.21b)
Net Margin = 10.83% (Net Income TTM 781.0m / Revenue TTM 7.21b)
Gross Margin = 44.12% ((Revenue TTM 7.21b - Cost of Revenue TTM 4.03b) / Revenue TTM)
Gross Margin QoQ = 45.71% (prev 42.60%)
Tobins Q-Ratio = 1.67 (Enterprise Value 8.60b / Total Assets 5.16b)
Interest Expense / Debt = 4.58% (Interest Expense 269.0m / Debt 5.87b)
Taxrate = 19.57% (190.0m / 971.0m)
NOPAT = 970.8m (EBIT 1.21b * (1 - 19.57%))
Current Ratio = 1.20 (Total Current Assets 2.05b / Total Current Liabilities 1.71b)
Debt / Equity = -5.57 (negative equity) (Debt 5.87b / totalStockholderEquity, last quarter -1.05b)
Debt / EBITDA = 3.50 (Net Debt 5.08b / EBITDA 1.45b)
Debt / FCF = 4.93 (Net Debt 5.08b / FCF TTM 1.03b)
Total Stockholder Equity = -1.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.67% (Net Income 781.0m / Total Assets 5.16b)
RoE = -61.76% (negative equity) (Net Income TTM 781.0m / Total Stockholder Equity -1.26b)
RoCE = 57.44% (EBIT 1.21b / Capital Employed (Equity -1.26b + L.T.Debt 3.37b))
RoIC = 27.46% (NOPAT 970.8m / Invested Capital 3.54b)
WACC = 6.31% (E(3.52b)/V(9.39b) * Re(10.69%) + D(5.87b)/V(9.39b) * Rd(4.58%) * (1-Tc(0.20)))
Discount Rate = 10.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.15 | Cagr: -4.87%
[DCF] Terminal Value 77.97% ; FCFF base≈931.8m ; Y1≈1.07b ; Y5≈1.57b
[DCF] Fair Price = 92.13 (EV 23.7b - Net Debt 5.08b = Equity 18.6b / Shares 201.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 16.78 | EPS CAGR: 0.65% | SUE: 3.67 | # QB: 1
Revenue Correlation: -86.40 | Revenue CAGR: -0.95% | SUE: 0.39 | # QB: 0
EPS current Quarter (2026-10-31): EPS=0.11 | Chg30d=-55.88% | Revisions=-83% | Analysts=17
EPS current Year (2027-01-31): EPS=2.70 | Chg30d=+2.11% | Revisions=+24% | GrowthEPS=-15.8% | GrowthRev=-2.6%
EPS next Year (2028-01-31): EPS=2.79 | Chg30d=-2.61% | Revisions=-24% | GrowthEPS=+3.1% | GrowthRev=+1.7%
[Analyst] Revisions Ratio: -33% (up=14, down=29)